In response to a summertime resurgence in COVID-19 cases and in preparation for the upcoming respiratory virus season, the federal government is set to reinstate its free at-home testing program in late September.1 The initiative was previously paused in March due to declining case numbers following the winter respiratory season.
The government said the tests will “detect current COVID-19 variants and can be used through the end of the year.”2 US households will be eligible to order 4 free COVID-19 tests at COVIDTests.gov when the program resumes.
- The US government is reinstating its free at-home COVID-19 testing program in late September due to a summertime resurgence in cases.
- The government has now made free tests available to all Americans 7 times in the past 3 years, responding to fluctuating COVID-19 case numbers.
- The resumption of the program aligns with the FDA approval and EUA of new COVID-19 vaccination formulations that offer stronger protection against circulating variants.
"As families start to move indoors this fall and begin spending time with their loved ones, both very old and very young, they will once again have the opportunity to order up to 4 new COVID-19 tests free of charge and have them sent directly to their homes," said Dawn O’Connell, assistant secretary for preparedness and response at the Department of Health and Human Services, in an ABC News report.1 "These tests will help keep families and their loved ones safe this fall and winter season."
In July, the CDC estimated that COVID-19 infections are growing or likely growing in 45 states and territories.3 The currently dominant SARS-CoV-2 subvariant is the FLiRT variant, which according to Andew Pekosz, PhD, professor of molecular microbiology and immunology at the Johns Hopkins Bloomberg School of Public Health in a Q&A published on the university’s website, encompasses “a whole family of variants—including KP.2, JN. 1.7, and any other variants with KP or KN—that appear to have independently picked up the same set of mutations.”4
And although hospitalizations and deaths haven’t seen a rise proportionate to cases, health officials continue to emphasize the importance of COVID-19 vaccination. A major concern, however, is the effectiveness of current vaccines against emerging variants.
Addressing this, the FDA recently approved and granted emergency use authorization for updated COVID-19 vaccines manufactured by Moderna and Pfizer to include a monovalent component targeting the KP.2 variant. The agency assured in a news release that the formulations now “more closely target currently circulating variants and provide better protection against serious consequences of COVID-19.”5
READ MORE: COVID-19: FDA Approves, Grants EUA to Moderna, Pfizer 2024-2025 Vaccine Formulations